International Journal of Mental Health & PsychiatryISSN: 2471-4372

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Therapeutic Effects of Add-On Aceclofenac to Escitalopram in Patients with Depression: An Assessor-Blind, Randomized Clinical Study

Lower response and remission rates with current anti- depressants highlight the need for new treatment approaches in patients with depression. There is abundant literature suggesting non-steroidal anti-inflammatory drugs as an add-on therapy to improve outcomes in patients with depression. We investigated efficacy and safety of add-on aceclofenac alone and/or in-combination with serratiopeptidase to escitalopram in patients with depression. One-hundred and two patients with depression participated in randomized, assessor- blind, parallel group clinical study and underwent 12 weeks of treatment of following: a) add-on aceclofenac monotherapy (200mg/day) to escitalopram (20mg/day) a) add-on fixed-dose combination of aceclofenac and serratiopeptidase (200+30mg/ day) to escitalopram (20mg/day) c) escitalopram monotherapy (20mg/day). Efficacy measures included the 17-item Hamilton depression rating scale (HAM-D17) total score (primary end- point), Montgomery–Asberg depression rating score (MADRS) and biomarkers levels like interleukin-6, cortisol and brain- derived neurotrophic factor (BDNF). Repeated-measure analysis demonstrated significant effect for the product of time and treatment interaction on the HAM-D17 score for both above stated add-on study treatments to escitalopram (p<0.001). Patient receiving add-on aceclofenac monotherapy or its combination with serratiopeptidase to escitalopram have shown significant reduction in HAM-D17 score and MADRS score along with the decline (p<0.05) in IL-6 levels and cortisol levels at week 12. In addition, both add-on treatment groups to escitalopram have also shown significant improvement in BDNF levels as compared to escitalopram monotherapy group. The antidepressant activity of add-on aceclofenac monotherapy or its combination with serratiopeptidase to escitalopram might be linked to their capability of reducing IL-6 and cortisol concentrations along with significant rise in BDNF level.

Special Features

Full Text


Track Your Manuscript

Media Partners